Zanjan, IRNA – Director of Pasteur Institute of Iran Alireza Biglari said the joint vaccine developed by Finlay Vaccine Institute of Cuba and the Pasteur Institute of Iran is 100% effective on severe types and deaths caused by the COVID-19.

Speaking to IRNA, Biglari said the effectiveness of the SOBERANA 02 vaccine together with the SOBERANA + booster has been 91.2% in clinical trials, meaning that the vaccine is 100% effective on severe types.

He noted that SOBERANA 02 effectiveness had earlier been reported 62% in Cuba.

Earlier, Finlay Vaccine Institute of Cuba and the Pasteur Institute of Iran in a joint statement announced that Tehran and Havana are conducting strategic cooperation in producing coronavirus vaccine.

'Based on the successful development by the Finlay Institute of the SOBERANA 02 vaccine against COVID-19 and that it uses the same technological platform of the Cuban anti-pneumococcal vaccine, which had been the subject of a Technology Transfer Agreement, both institutions agreed to include in the said contract the transfer of technology for the production in Iran of SOBERANA 02, they added.

'The cooperation of these two prestigious Cuban-Iranian institutions will have a positive impact on the health of the population of both countries,' they reiterated.

9376**1424

Follow us on Twitter @IrnaEnglish